Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

Needs-based epilepsy follow-up: seizure control, treatment adherence and patient care.

Epilepsy & behavior : E&B·2026
Same author

Myasthenia gravis complicated with autoimmune encephalitis: a review.

Frontiers in neurology·2026
Same author

The Prevalence and Incidence of Cluster Headache: A Norwegian Population-Based Time-Trend Study.

Neurology·2026
Same author

Risk of neurodevelopmental disorders after fetal topiramate exposure: a systematic review.

Frontiers in drug safety and regulation·2026
Same author

Timing of high-dose folic acid supplementation in the periconceptional period among women taking antiseizure medications and risk of major congenital anomalies: a target trial emulation.

Journal of neurology, neurosurgery, and psychiatry·2026

Related Experiment Video

Updated: Jun 25, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Autoimmune myasthenia gravis.

Nils Erik Gilhus1

  • 1Department of Clinical Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway. nils.gilhus@nevro.uib.no

Expert Review of Neurotherapeutics
|March 11, 2009
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission. Current treatments manage symptoms and improve quality of life, but antigen-specific therapies are still under development.

Related Experiment Videos

Last Updated: Jun 25, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Myasthenia gravis (MG) is an autoimmune neuromuscular transmission disorder.
  • Pathogenesis involves autoantibodies against muscle and muscle cell membrane molecules.
  • MG subtyping is crucial for treatment decisions.

Purpose of the Study:

  • To review the current understanding and management of Myasthenia Gravis.
  • To highlight the importance of MG subclassification for tailored treatment strategies.
  • To discuss the diagnostic process and therapeutic options for MG patients.

Main Methods:

  • Diagnostic procedures include neurophysiology, neuroimmunology, neuropharmacology, and imaging.
  • Treatment involves symptomatic therapy (acetylcholine esterase inhibitors), thymectomy, and immunosuppressive drugs.
  • Experimental strategies for antigen-specific therapies are being explored.

Main Results:

  • Six MG categories are identified: Ocular MG, early-onset MG, late-onset MG, MG with thymoma, MG with anti-MuSK antibodies, and antibody-negative MG.
  • Established treatments yield good-to-excellent results for most patients, ensuring acceptable quality of life and no increased mortality.
  • Acute and intensive care during MG exacerbations are critical.

Conclusions:

  • Current MG treatments are effective for symptom management but lack antigen specificity.
  • Further research is needed to develop curative or antigen-specific therapies for Myasthenia Gravis.
  • Despite limitations, established treatments provide good outcomes for the majority of MG patients.